drugset / Trial / NCT00611728
Ph I SU011248 + Irinotecan in Treatment of Pts w MG
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary Objectives To determine maxi tolerated dose \& dose limiting toxicity of SU011248 + Irinotecan in recurrent MG pts not on EIAEDs To characterize safety \& tolerability of SU011248 + Irinotecan among pts w recurrent MG Secondary Objectives To evaluate pharmacokinetic profile of SU011248 \& Irinotecan when co-administered in pts w MG To evaluate anti-tumor activity of SU011248 + Irinotecan
Timeline
- Start
- 2008-03
- Primary completion
- 2010-06
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Subject | Sunitinib | Small molecule | — | Oral |